Systemic Lidocaine Infusions for Pediatric Patients with Cancer-Related Pain.
Emily Simon RavRachna ShethAli H AhmadPublished in: Children (Basel, Switzerland) (2022)
Pediatric patients with cancer experience significant distress from both treatment and cancer-related pain. Careful selection of an analgesic regimen should be based upon individual patient factors, including the level of pain, response to therapy, and physiologic profile. Refractory pain is a therapeutic dilemma frequently encountered in the pediatric cancer setting. Systemic lidocaine infusions have been described as both safe and efficacious, as prior studies show patients reporting decreased pain scores and improved quality of life after lidocaine treatment. Given the favorable side effect profile of lidocaine, it has the potential to be considered for analgesia in the setting of refractory pain. This review discusses the use of systemic lidocaine infusions for analgesia in pediatric oncology patients with cancer-related pain.
Keyphrases
- chronic pain
- pain management
- neuropathic pain
- postoperative pain
- squamous cell carcinoma
- emergency department
- ejection fraction
- spinal cord injury
- palliative care
- newly diagnosed
- climate change
- mesenchymal stem cells
- risk assessment
- papillary thyroid
- bone marrow
- combination therapy
- human health
- lymph node metastasis